NEWM&A

Bayer (BAYRY) Loses Bid Against Johnson & Johnson Prostate Drug Claims

Published on 4/18/2026

#BAYRY#JNJ#pharmaceuticals#legal#litigation
Bayer (BAYRY) Loses Bid Against Johnson & Johnson Prostate Drug Claims

AI Summary

A US judge rejected Bayer's (BAYRY) motion to block claims regarding Johnson & Johnson's (JNJ) prostate cancer drug. This ruling may affect Bayer's legal exposure related to similar product liabilities. The case underscores ongoing competitive pressures in the pharmaceutical sector, particularly regarding patent and claim disputes. Bayer's strategy and resource allocation may be impacted by this decision as they navigate the legal landscape.

Source: Read original article (opens in new tab)

Related News

Nexstar (NXST) Merger with Tegna Temporarily Frozen by Court
M&A

Nexstar (NXST) Merger with Tegna Temporarily Frozen by Court

Apr 18

Navan (NVN) Chief Accounting Officer Departure Announced
M&A

Navan (NVN) Chief Accounting Officer Departure Announced

Apr 17

Liberty Energy (LBRT) Shareholders Re-elect Directors with Majority Vote
M&A

Liberty Energy (LBRT) Shareholders Re-elect Directors with Majority Vote

Apr 17

Elemental Royalty (ELE) Price Target Raised to C$38 by Canaccord
M&A

Elemental Royalty (ELE) Price Target Raised to C$38 by Canaccord

Apr 17